Significant Customers was Retractable Technologies’s largest product and service line in fiscal 2025, bringing in $20.60M of $35.17M (59%).
| Product and Service | FY 2022 | FY 2023 | FY 2025 |
|---|---|---|---|
| U.S. Sales (Excluding U.S. Government) | $29.28M | $26.12M | — |
| Significant Customers | — | — | $20.60M |
| Sales To U.S. Government | $15.73M | — | — |
| North & South America Sales (Excluding U.S.) | $28.72M | $5.86M | $3.19M |
| U.S. Sales | — | — | $9.78M |
| Other International Sales | $13.00M | $2.18M | $1.61M |
| Total | $86.74M | $34.16M | $35.17M |
Retractable Technologies brought in $35.17M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. Retractable Technologies regrouped these lines after fiscal 2023, so the total does not compare directly with that year's $34.16M. Significant Customers was the largest at $20.60M (58.6%), ahead of U.S. Sales at $9.78M (27.8%) and North & South America Sales (Excluding U.S.) at $3.19M (9.1%). The remaining line, Other International Sales, brought in $1.61M.
Compared with fiscal 2023, the previous year with figures, Other International Sales fell 26.0% to $1.61M and North & South America Sales (Excluding U.S.) fell 45.6% to $3.19M.
Retractable Technologies began breaking out Significant Customers in fiscal 2025 and U.S. Sales in fiscal 2025. Retractable Technologies stopped reporting U.S. Sales (Excluding U.S. Government) ($26.12M in fiscal 2023) and Sales To U.S. Government ($15.73M in fiscal 2022) as separate lines.
Syringes was Retractable Technologies’s largest product and service line in fiscal 2025, bringing in $21.08M of $32.25M (65%).
| Product and Service | FY 2016 | FY 2017 | FY 2023 | FY 2025 |
|---|---|---|---|---|
| Syringes | $26.12M | $21.08M | ||
| Easypoint Needles | $7.03M | $9.78M | ||
| Easy Point Needles | — | — | ||
| Blood Collection Products | $1.93M | $1.34M | ||
| Licensing Fees | $778.00K | — | ||
| Other Products | $266.27K | $43.63K | ||
| Total | $36.12M | $32.25M |
Retractable Technologies brought in $32.25M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. That is less than the $35.17M it reports by product and service, so these lines do not cover all of its revenue. Syringes was the largest at $21.08M (65.4%), ahead of Easypoint Needles at $9.78M (30.3%) and Blood Collection Products at $1.34M (4.2%). The remaining line, Other Products, brought in $43.63K.
Compared with fiscal 2023, the previous year with figures, Easypoint Needles grew fastest, up 39.1% to $9.78M, while Blood Collection Products fell the most, down 30.2% to $1.34M. Some of that change comes from Retractable Technologies regrouping its lines.
Retractable Technologies stopped reporting Licensing Fees as a separate line after fiscal 2023, when it brought in $778.00K.
U.S. Sales was Retractable Technologies’s largest region in fiscal 2019, bringing in $26.72M of $35.64M (75%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| U.S. Sales | — | — | — | $26.72M | ||||||
| U.S | — | $23.79M | $23.80M | — | ||||||
| United States | $26.31M | $27.02M | — | — | ||||||
| Salesrevenuenet | — | — | — | — | ||||||
| Revenue, Net | — | — | — | — | ||||||
| North & South America (Excluding U.S) | — | — | — | $7.86M | ||||||
| North & South America Sales (Excluding U.S.) | $2.64M | $6.18M | $3.52M | — | ||||||
| North & South America Excluding United States | $2.74M | $6.38M | — | — | ||||||
| Other International Sales | $744.64K | $1.03M | $940.74K | $1.05M | ||||||
| Other International | $776.87K | $1.10M | — | — | ||||||
| Total | $33.21M | $65.50M | $28.27M | $35.64M |
Retractable Technologies brought in $35.64M from its three regions in fiscal 2019, the year ended December 31, 2019. Retractable Technologies regrouped these regions after fiscal 2018, so the total does not compare directly with that year's $28.27M. U.S. Sales was the largest at $26.72M (75.0%), ahead of North & South America (Excluding U.S) at $7.86M (22.1%) and Other International Sales at $1.05M (3.0%).
Retractable Technologies began breaking out U.S. Sales in fiscal 2019 and North & South America (Excluding U.S) in fiscal 2019. Retractable Technologies stopped reporting United States ($27.02M in fiscal 2017), U.S ($23.80M in fiscal 2018), North & South America Excluding United States ($6.38M in fiscal 2017) and two others as separate regions.
Retractable Technologies (RVP) reports its revenue by product and service and by geography. In fiscal 2025, Significant Customers was its largest product and service line, bringing in $20.60M (58.6% of the total), followed by U.S. Sales at $9.78M (27.8%).
Significant Customers was Retractable Technologies' largest product and service line in fiscal 2025, bringing in $20.60M, or 58.6% of the $35.17M total across its four product and service lines.
U.S. Sales was Retractable Technologies' largest region in fiscal 2019, bringing in $26.72M, or 75.0% of the $35.64M total across its three regions.
Every figure comes from Retractable Technologies' annual financial filings, as reported. Each line keeps the name Retractable Technologies gives it, and years follow its fiscal calendar.
Retractable Technologies' revenue by product and service goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.